Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — ANGLE — Proactive One2One Investor Forum 2024
16 slides from Cellbxhealth's conference presentation, Oct 24, 2024
Slide 1: Transforming cancer care with the first FDA cleared medical device for CTC capture and harvest
Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumour cells Proactive One2One Investor Forum 24 October 2024 Andrew Newland and Ian Griffiths
Slide 2: Forward looking statements
LSE AIM:AGL OTCQX:ANPCY Forward looking statements This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be abound by the following conditions. The presentation slides which follow this notice and the oral presentati
Slide 3: ANGLE – transforming cancer care
ANGLE – transforming cancer care Our Mission: Parsortix® instrument FDA INTENDED USE Enable personalised cancer care with a simple blood test to guide treatment, The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich improving patient outcomes and reducing circulating tumor ce
Slide 4: Third-party evidence
Third-party evidence • FDA and EU clearance expected to give ANGLE first mover advantage As of September 2024 in non-invasive repeat testing of intact cancer cells Clinically relevant biomarkers 88% published in including: • >260 Parsortix systems in use EGFR BRAF 40 high impact journals* 42 publica
Slide 5: Personalised cancer care is now essential
Personalised cancer care is now essential Estimated number of new cancer cases from 2022-20504 18.7 million new cancer cases p.a. with a further 49.3 million people diagnosed in the previous five years1 77% growth in cancer cases by 2050 with global cancer cases expected to increase from 20.0m in 20
Slide 6: Large Pharma need Parsortix solutions
Large Pharma need Parsortix solutions Large Pharma customers Biopharma customers © ANGLE plc 2024 6
Slide 7: Parsortix system addresses critical need for Large Pharma
Parsortix system addresses critical need for Large Pharma • Next generation blockbuster drugs need companion diagnostics (new classes of drugs: ADCs, DDR inhibitors, immunotherapy combinations) • Clonal evolution of cancer critical to disease progression requires real-time non-invasive assessment (s
Slide 8: Large Pharma revenue build: multiple shots on goal
Large Pharma revenue build: multiple shots on goal • Assay development and pilot studies c. £200,000 Pharma companion diagnostic pathway - indicative only Revenue Potential Year 1 Phase 1 £0.2m to £0.7m Years 2-3 Phase 2 £1.2m to £3.6m Years 4-5 Phase 3 £15m to £45m Year 6 onwards Companion Diagnost
Slide 9: Eisai: HER2 breast cancer. ADC a new class of drug
Eisai: HER2 breast cancer. ADC a new class of drug Global Japanese pharma company • Revenues >£3.7 billion3 >10,000 employees • >70 active oncology clinical trials >50,000 participants • HER2 targeting antibody-drug conjugate (ADC) being co-developed by Eisai and Bliss Biopharmaceutical Co., Ltd as
Slide 10: AstraZeneca: DDR multiple cancers
AstraZeneca: DDR multiple cancers Global pharma company with major oncology focus contributing to 39% of total product sales1 " It is through our science- • 459 active, interventional cancer clinical trials in 139,000 patients driven approach in targeting • Therapies targeting DNA Damage Response fo
Slide 11: AstraZeneca: AR prostate cancer
AstraZeneca: AR prostate cancer AR plays a pivotal role in Androgen Receptor (AR) detection assay for use in prostate cancer, especially castration-resistant prostate AstraZeneca’s prostate cancer studies cancer (CRPC). • 12-month development phase worth £550,000 CRPC is incurable and can • ANGLE's
Slide 12: Recursion Pharmaceuticals: multiple cancers
Recursion Pharmaceuticals: multiple cancers • Clinical-stage biotechnology company leveraging technology, including machine learning and AI, to industrialise drug discovery • Five research programmes in clinical development, with a further two in preclinical development and 12 in early discovery • M
Slide 13: Critical DNA mutation information enabled by Parsortix
Critical DNA mutation information enabled by Parsortix Dual CTC-DNA and ctDNA analysis • Results from 47 cancer patients DNA variants found in CTCs with FDA cleared drugs for the variants in tissue or plasma • Actionable DNA variants found in CTCs not including in ctDNA in 70% of breast and lung pat
Slide 14: Exclusive rights secured NGS pan-cancer DNA panel
Exclusive rights secured NGS pan-cancer DNA panel “CTCs represent a transformative biomarker in precision oncology, offering extraordinary opportunities to translate scientific discoveries into • Cutting-edge genomics and molecular diagnostics company tangible improvements in patient care… • Option
Slide 15: Building numerous shots on goal
Building numerous shots on goal • Three large pharma contracts already, all progressing well towards with future revenue growth potential • Multiple cross-sell opportunities with existing large pharma customers • Multiple additional large pharma and corporate contracts under discussion • Molecular a
Slide 16: ANGLE plc contact details
ANGLE plc 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom angleplc.com © ANGLE plc 2024 16